AP
LXRX icon

AHL Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

AHL Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-85,489
Closed -$1.18M – 1209
2016
Q4 		$1.18M Buy
85,489
+44,374
+108% +$712K 0.04% 629
2016
Q3 		$743K Buy
+41,115
New +$662K 0.03% 677

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AHL Partners's LXRX Position: Q1 2017 in Review

AHL Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 85,489 shares — an estimated $1.18M sold.

AHL Partners first reported a position in LXRX in Q3 2016 and held it in 2 quarters. The position peaked at $1.18M in Q4 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

  • AHL Partners reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • AHL Partners sold 85,489 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $1.18M.
  • AHL Partners first reported a position in Lexicon Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • AHL Partners's Lexicon Pharmaceuticals position peaked at $1.18M in Q4 2016.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on AHL Partners's 13F filing for Q1 2017, filed 15 May 2017.